Cargando…
How can Cytokine-induced killer cells overcome CAR-T cell limits
The successful treatment of patients affected by B-cell malignancies with Chimeric Antigen Receptor (CAR)-T cells represented a breakthrough in the field of adoptive cell therapy (ACT). However, CAR-T therapy is not an option for every patient, and several needs remain unmet. In particular, the prod...
Autores principales: | Cappuzzello, Elisa, Vigolo, Emilia, D’Accardio, Giulia, Astori, Giuseppe, Rosato, Antonio, Sommaggio, Roberta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477668/ https://www.ncbi.nlm.nih.gov/pubmed/37675107 http://dx.doi.org/10.3389/fimmu.2023.1229540 |
Ejemplares similares
-
Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies
por: Cappuzzello, Elisa, et al.
Publicado: (2016) -
Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells
por: Sommaggio, Roberta, et al.
Publicado: (2020) -
Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells
por: Pietà, Anna Dalla, et al.
Publicado: (2021) -
Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1
por: Tosi, Anna, et al.
Publicado: (2017) -
How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover, Maya, et al.
Publicado: (2021)